Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances: 2009-2023
Historic Short-Term Debt issuances for Teva Pharmaceutical Industries (TEVA) over the last 11 years, with Sep 2023 value amounting to $700.0 million.
- Teva Pharmaceutical Industries' Short-Term Debt issuances was N/A to $700.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.6 billion, marking a year-over-year change of. This contributed to the annual value of $700.0 million for FY2023, which is N/A change from last year.
- As of Q3 2023, Teva Pharmaceutical Industries' Short-Term Debt issuances stood at $700.0 million, which was up 250.00% from $200.0 million recorded in Q4 2021.
- Over the past 5 years, Teva Pharmaceutical Industries' Short-Term Debt issuances peaked at $700.0 million during Q3 2023, and registered a low of -$1.0 million during Q1 2019.
- In the last 2 years, Teva Pharmaceutical Industries' Short-Term Debt issuances had a median value of $450.0 million in 2021 and averaged $450.0 million.
- In the last 5 years, Teva Pharmaceutical Industries' Short-Term Debt issuances skyrocketed by 9,900.00% in 2019 and then tumbled by 37.30% in 2021.
- Quarterly analysis of 4 years shows Teva Pharmaceutical Industries' Short-Term Debt issuances stood at $404.0 million in 2019, then dropped by 21.04% to $319.0 million in 2020, then tumbled by 37.30% to $200.0 million in 2021, then reached $700.0 million in 2023.
- Its Short-Term Debt issuances stands at $700.0 million for Q3 2023, versus $200.0 million for Q4 2021 and $319.0 million for Q4 2020.